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Abstract
Aim: To investigate the serotonin and von Willebrand factor (vWF) concentrations among unstable angina (UA)
patients without and with progression toward myocardial infarction (outcome) and to assess the utility of both as
prognostic markers of UA complications.
Materials and methods: In observational cohort study, we recruited 103 patients with ischemic heart disease
(the median age 65.0 (59.0-69.0) years, 45 females (43.7%)). After full set of investigations including high
sensitive Troponin I test and 28-day follow-up period, we defined three groups: Group 1 – stable angina patients
(n=22) as control, Group 2 – UA patients without outcome (n=71), Group 3 – UA patients with outcome (n=10).
We analyzed the blood plasma serotonin content by the ion-exchange chromatography with measurement of
serotonin on fluorescence spectrophotometer. VWF concentration was determined by ELISA. We compared
the concentrations of observed parameters among the groups with the Kruskal-Wallis test (with post-hoc
Mann-Whitney test with Bonferroni-Holm correction). We assessed binary logistic models, receiver operating
characteristic curves, calculated sensitivity (Se), specificity (Sp), and positive likelihood ratio (LR+) for each
indicator.
Results: We registered elevation in serotonin concentration and decline in vWF concentration in Group 3 in
comparison with Group 2 (22.670 (20.687-24.927) µg/ml vs 11.980 (8.120-15.000) µg/ml, p < 0.001, and
0.117 (0.109-0.120) rel.units/ml vs 0.134 (0.127-0.143) rel.units/ml, p < 0.001) and Group 1 (12.340 (10.052-
13.619) µg/ml, p < 0.001, and 0.137 (0.127-0.156) rel.units/ml, p < 0.001), respectively. No significant differences
in serotonin and vWF concentrations between Group 1 and Group 2 were detected (p=0.81 and p=0.36,
respectively). The probability of outcome increased significantly (by 60.7% and 59.7%, LR+ 19.0 [6.0, 60.0] and
18.0 [3.9, 80.0]) if serotonin concentration was above 21.575 µg/ml (Se=80.0%, Sp=95.8%, AUC=0.975) and
vWF concentration was below 0.114 rel.units/ml (Se=50.0%, Sp=97.2%, AUC=0.973), respectively.
Conclusions: Serotonin and vWF as biomarkers are demonstrated promising results for rule-in the patients
with risk of short-term UA progression toward myocardial infarction.
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Problem statement and analysis of the
latest research
Ischemic heart disease (IHD) occupies the primary position
among all causes of death worldwide [1] despite the descen-
dent trend in age-standardized acute myocardial infarction
(MI) incidence and unstable angina (UA) prevalence over
the past two decades [2]. Moreover, due to the overall growth
of the population and its aging, the global burden of IHD
has increased by 29% to 29 million disability-adjusted life
years [2].
IHD as an umbrella term comprises two principal groups
of conditions, namely chronic and acute coronary syndromes.
It is the latter state that is the main killer globally, whereas
those with chronic coronary syndrome have annual mortality
of less than 2% [3]. Yet, the mortality within acute coronary
syndrome groups differs drastically as well. Thus, short-term
mortality following MI with ST-segment elevation (STEMI)
and non-ST-segment elevation MI (NSTEMI) is reported to
be significantly higher than that one following UA (7% vs
3.7-7.4% vs 0.5-0.7%) [4, 5], but future non-fatal MI is com-
parable in UA and NSTEMI withal (11.2% vs 7.9%, respec-
tively) [5]. Consequently, UA does need further investigations,
especially taking into account the risk of its progression to-
wards MI and the current guidelines recommendations of early
discharge after individualized risk stratification [6].
Atherosclerotic plaque disruption and subsequent throm-
bus formation are considered to be the prevailing processes
of atherothrombosis with acute coronary syndrome (ACS)
onset. The activation of platelets and the coagulation cascade
are the main mechanisms leading to thrombus formation and
propagation [7]. As platelets play a crucial role in develop-
ment of UA and NSTEMI [8] we have focused on platelets.
Damage of the endothelium provokes contact of exposed col-
lagen with platelet glycoprotein receptors of different types
through von Willebrand factor (vWF) [9]. Platelet activation
is attended by the change of its shape and release of adenosine
diphosphate, 5-hydroxytryptamine (serotonin), and thrombox-
ane A2. Adenosine triphosphate, ectonucleoside triphosphate
diphosphohydrolase-1, C-type lectin-like receptor 2, disinte-
grin and metalloprotease with a thrombospondin type 1 motif
13 (ADAMTS-13) are other modulators of platelet activation.
VWF/ADAMTS-13 axis is one more link that controls the in-
tensity of thrombus formation [7].
Despite the mechanism of plaque instability, thrombus
formation and propagation have been investigated thoroughly,
the prognostic markers of IHD progression from stable angina
(SA) toward UA and further MI remains obscure.
Objective: Our study was aimed to investigate the changes
of serotonin and vWF concentrations among UA patients with
and without progression toward MI and to assess the observed




In this observational cohort study, we enrolled patients who
were hospitalized to the cardiology department with UA and
out-hospital patients with SA (as the control group).
We followed the guidelines of the European Society of
Cardiology 2020 [6] and 2019 [10] to establish the diagno-
sis and manage the patients with UA and SA, respectively.
Thus, we used three groups of criteria: complaints, electro-
cardiogram (ECG) at rest, biochemical markers (quantitative
high-sensitive cardiac Troponin I (hs-cTnI) test). Regarding
the latter, we checked it only in UA patients at admission as
one of the MI exclusion criterion. SA patients had unchanged
ECG (in comparison with the ECG archive of the patient), no
complaints or any other signs typical of ACS. Consequently,
there were no need in hs-cTnI control. We collected the blood
for observed hemostatic parameters analysis before treatment
onset (UA patients) or after recruitment (SA patients). All
UA patients received standard treatment, namely anticoag-
ulant, acetylsalicylic acid, clopidogrel, high dose of statin,
nitrates, β -blocker (depending on heart rate), and angiotensin-
converting enzyme inhibitor (for blood pressure correction),
while SA patients were continuing basic treatment. We took
blood samples for routine analysis on the next day after ad-
mission or recruitment (in case of SA patients) after a 12-hour
fasting period. Also, we performed two-dimensional transtho-
racic echocardiography (2D-TTE). We registered ECG at rest
in dynamic at least twice a day and on-demand in UA patients.
While most of the UA patients were treated with good
results (87.7%) (Group 2), the clinical condition of 10 UA
patients worsened on the 3rd-5th day of treatment (12.3%)
(Group 3). ECG changes associated with complaints and
significantly increased hs-cTnI level (128 (94-301 pg/ml) con-
firmed the MI onset. STEMI was registered in 1 patient, while
NSTEMI was diagnosed in 9 patients. These patients were
transferred to a specialized clinic.
Population
Finally, we enrolled 103 patients with a median age of 65.0
(59.0-69.0) years, 45 females (43.7%).
After a 28-day follow-up period, we defined three groups:
Group 1 – SA patients (n=22), Group 2 – UA patients without
progression toward MI (n=71), and Group 3 – UA patients
with MI as a complication (n=10).
The exclusion criteria were conditions with significant
influence on the hemostatic system as well as troponin level
such as the history of MI or stroke, heart defects, persistent
form of atrial fibrillation/ atrial flutter, cardiomyopathies, non-
ischemic myocardial injuries, heart failure IIB-III stage, blood
diseases including coagulopathies, anemia of II-III stage, se-
vere renal dysfunction (glomerular filtration rate GFR < 30
ml/min./1.73 m2), hepatic dysfunction, malignancy, recent
(within 6 months) traumas and bleedings, endocrinological
disorders, active infection, chronic diseases in the period of
exacerbation.
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Blood analysis
At admission before treatment onset venous whole blood sam-
ples were drawn by phlebotomy in sodium citrate (38 g/l at
the final ratio of 9:1 vol/vol) with further centrifugation for
40 minutes at 900 g. Plasma samples were aliquoted and
frozen at -80◦C until use. We analyzed the concentrations of
vWF by enzyme-linked immunosorbent assays with primary
and secondary antibodies from Santa Crus Biotechnology,
CA, USA according to the manufacturer’s instructions. We
assayed the concentration of serotonin by the ion-exchange
chromatography on the KM-Sepharose method [11] with fur-
ther measurements of serotonin on fluorescence spectropho-
tometer at an excitation wavelength of 295 nm and absorption
wavelength of 550 nm against samples containing distilled
water [12].
A set of routine analyses was performed by the laboratory
of the hospital. Samples were collected after an overnight fast.
The laboratory equipment was calibrated.
Hs-cTnI was analyzed by chemiluminescent immunoassay
(reference ranges - < 57.27 pg/ml for males, < 36.99 pg/ml –
for females).
Glomerular filtration rate (GFR) was calculated using
the CKD-EPI formula.
Body mass index (BMI) was defined as weight in kilo-
grams divided by height in meters squared.
Instrumental procedures
We recorded 12-lead surface resting-ECG manually at a sweep
of 25 mm/s. We paid attention to ST-segment depression or
elevation, pathological T-wave inversion, new-onset left bun-
dle branch block, arrhythmias. ST-segment elevation was
defined as a J-point elevation of ≥ 2 mm in precordial leads
and ≥ 1 mm in limb leads. ST-segment depression was de-
fined as a J-point decline of ≥ 1.5 mm in precordial leads
and ≥ 1 mm in limb leads. We referred horizontal, downslop-
ing ST-segment depression to ischemic changes on ECG. Dis-
cordant T-waves detected in 2 anatomically contiguous leads
were considered a sign of post-ischemic changes.
We measured the blood pressure of patients three times
in the admission department using standardized electronic
measuring instruments.
2D-TTE was conducted by one expert sonologist using
the ultrasound unit of the expert class. We used current 2D-
TTE scanning guidelines by Mitchell et al. [13]. The apical
four-chamber and two-chamber views, parasternal short and
long axis, thoracic aorta, upper abdominal aorta, and inferior
vena cava were visualized. Also, we assessed wall movements.
Valves were evaluated with color Doppler imaging.
Statistical analysis
We used SPSS (version 22.0, IBM Corp, USA) for data anal-
ysis. Continuous variables were reported as medians (in-
terquartile range) (Me (IQR)), and categorical variables as
absolute numbers and percentages. For comparison of con-
tinuous variables among three groups, we used the Kruskal-
Wallis test with further post-hoc Mann-Whitney test with
Holm-Bonferroni correction for paired comparison. The χ2
test was used for categorical variables. A binary logistic re-
gression was developed to check if observed parameters as
independent variables may be useful for the identification of
UA patients with progression toward MI. To create the mod-
els, we used the ”enter” method. For model fit statistics, we
included results of the chi-square likelihood ratio test, pseudo-
R-square values, assessment of the classification tables, re-
gression weight coefficient, and defined which independent
parameter might be useful. Also, we assessed the true positive
rate (TPR) and true negative rate (TNR) of each model. Re-
garding our study, the model’s TPR reflected the parameter’s
prediction accuracy to determine UA patients without risk of
progression towards MI. At the same time, the TNR reflected
the classifier’s ability to detect UA patients with progression
toward MI. In other words, TPR and TNR are the sensitivity
(Se) and specificity (Sp) of the models respectively. Also, we
used bootstrap optimism correction for model validation (sim-
ple sampling method, 1000 samples, 95% confidence interval
(CI)).
We constructed receiver operating characteristic curves
(ROC-curves) with main points like the area under the curve
(AUC) (95% CI), Sp, Se, and cut-off point.
Finally, we calculated positive likelihood ratios (LR+),
which provide medical practitioners with information about
the probability of abnormality without depending on the preva-
lence of abnormality in the study, unlike predictive values [14].
The latter fact was of high-importance in our study as the preva-
lence of abnormality (UA progression toward MI) was 12.3%.
All tests where possible were 2-tailed. P < 0.05 was
considered statistically significant.
Results
The groups are comparable by baseline characteristics, which
are presented in Table 1. The concentrations of observed
hemostatic parameters are demonstrated in Fig. 1 and Fig. 2.
In terms of both observed hemostatic parameters, we reg-
ister no significant difference between Group 1 and Group 2,
unlike Group 3 which differs remarkably from both above-
mentioned cohorts. While serotonin concentration in Group 3
is the highest among the observed groups, vWF concentration
is the lowest in this group.
As it is presented in Table 2, both models are significant
(p < 0.001) with supposed diagnostic properties. At first sight,
serotonin is more accurate in the detection of current abnor-
mality (80.0% vs 50.0%). However, this applies to the de-
tection of patients with UA without MI development, while
we are more interested in identifying a group of patients with
possible UA progression toward MI. Of note, serotonin and
vWF are characterized by opposite directions of the regression
coefficient, which is corresponding to Fig. 1 and Fig. 2.
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Figure 1. Serotonin concentration among observed groups.
Figure 2. Factor von Willebrand concentration among observed groups.
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Table 1. Baseline characteristics among the groups.
Parameter Group 1 Group 2 Group 3 pn=22 n=71 n=10
Age, years 62.5 (58.0-69.0) 66.0 (60.0-69.0) 61.0 (57.0-64.5) 0.19
Females, abs.no (%) 11.0 (50.0) 31 (43.7) 2 (25.0) 0.47
BMI, kg/m2 29.4 (26.1-32.0) 28.2 (25.2-32.2) 29.9 (26.1-32.1) 0.42
Smokers, abs.no (%) 1 (4.5) 13 (18.3) 3 (37.5) 0.03
Hs-cTnI, pg/ml - 25.0 (16.0-42.0) 29.0 (15.0-48.0) 0.68
TC, mmol/l# 5.2 (4.5-6.9) 5.1 (4.4-6.4) 5.1 (4.3-5.5) 0.73
TG, mmol/l
∫
2.6 (2.0-3.1) 2.1 (1.4-3.0) 2.9 (2.2-3.4) 0.08
LDLP, mmol/l# 2.6 (2.2-3.9) 3.1 (2.4-3.6) 2.2 (1.9-3.0) 0.45
HDLP, mmol/l# 1.4 (1.1-1.8) 1.2 (1.0-1.7) 1.0 (0.7-1.2) 0.06
ALT, IU/l 35.0 (25.0-55.0) 50.0 (45.0-60.0) 45.0 (40.0-60.0) 0.29
AST, IU/l 35.0 (30.0-46.0) 35.0 (30.0-40.0) 30.0 (25.0-45.0) 0.44
GFR, ml/min 59.0 (49.0-70.0) 61.0 (49.5-76.0) 60.0 (52.6-77.0) 0.57
Glucose, mmol/l¶ 4.8 (4.0-5.0) 4.4 (3.9-5.2) 4.7 (3.8-5.4) 0.36
WBC, ×109/l 7.6 (6.7-8.1) 7.8 (6.8-9.3) 8.1 (7.1-9.1) 0.06
RBC, ×1012/l 4.69 (4.27-5.15) 4.69 (4.31-5.10) 4.48 (4.23-5.00) 0.76
Hb, g/l 142.0 (131.0-148.0) 145.0 (135.0-165.0) 143.0 (134.0-160.0) 0.50
Platelets, ×109/l 304.0 (244.0-336.0) 250.0 (207.0-329.0) 280.0 (195.0-352.0) 0.34
ESR, mm/hour 10.0 (7.0-15.0) 15.0 (7.5-19.0) 16.0 (7.9-20.0) 0.16
ESV, ml 45.5 (29.0-54.6) 49.5 (41.0-62.0) 50.3 (42.7-63.0) 0.37
EDV, ml 109.3 (95.0-132.0) 118.0 (98.8-137.0) 115.0 (100.0-133.0) 0.58
EF, % 59.0 (57.5-63.0) 57.3 (50.7-62.0) 55.5 (51.3-61.8) 0.09
IVSd, mm 1.1 (0.9-1.3) 1.2 (1.1-1.3) 1.1 (1.0-1.3) 0.72
SBP, mmHg 134.0 (125.0-137.0) 145.0 (130.0-160.0) 147.0 (135.0-167.5) 0.03
DBP, mmHg 79.0 (74.0-82.0) 81.0 (74.0-92.0) 80.0 (76.0-94.0) 0.06
HR, beats/minute 72.0 (67.7-77.5)* 76.0 (70.0-85.0) 82.0 (78.5-98.0) 0.006
Notes: p – probability (Kruskal-Wallis H test except hs-cTnI where Mann-Whitney U test was used); * – significant difference between
Group 1 and Group 3 (post-hoc Mann-Whitney test with Holm-Bonferroni correction);
BMI – body mass index; Hs-cTnI – high sensitivity cardiac troponin I; TC – total cholesterol; TG – triglycerides; LDLP – low-density
lipoprotein cholesterol; HDLP – high-density lipoprotein cholesterol; ALT – alanine aminotransferase; AST – aspartate aminotransferase;
GFR – glomerular filtration rate; WBC – white blood cells, RBC – red blood cells, Hb – hemoglobin, ESR – erythrocyte sedimentation rate;
ESV – end-systolic volume; EDV – end-diastolic volume; EF – ejection fraction; IVSd – interventricular septum thickness at end-diastole;
SBP – systolic blood pressure; DBP – diastolic blood pressure; HR – heart rate.
Converting indexes: # – mg/dl = mmol/l × 38.66;
∫
– mg/dl = mmol/l × 88.5; ¶ – mg/dl = mmol/l × 18.02.
Afterward, we constructed and ROC-curves (Fig. 3 and
Fig. 4) and determined the main characteristics of the latter
(Table 3). Models with both serotonin and vWF were shown
to be suitable for the detection of patients with a risk of UA
transformation toward MI.
Thereafter, we aimed to analyze the utility of vWF and
serotonin for early rule-in pathways for UA progression to-
ward MI. For this purpose, we calculated LR+ with posterior
probability. These practical aspects are displayed in Table 3.
Thus, serotonin concentration above 21.575 µg/ml in-
creases the probability of UA progression toward MI by 60.7%
(LR+ 19.0), while concerning the decline in vWF concentra-
tion less than 0.114 rel.units/ml may be a significant predictor
of the outcome (LR+ 18.0).
Besides, taking into account the Se and Sp of indicators
as well as LR+, it looks like both factors are better applied to
rule-in the patients with UA progression toward MI, unlike to
rule out.
Discussion
Overall, two points are worthy to be highlighted. A significant
decrease in vWF concentration and increase in serotonin con-
centration are typical of UA patients with progression toward
MI. Both indicators have demonstrated a high ability to rule
in UA patients with risk of transformation into MI.
Enormous studies are dedicated to the issue of MI occur-
rence in IHD patients, particularly early MI diagnostic [15–
19]. However, there is limited data regarding risk factors for
UA transformation toward MI [20]. Currently, the hs-cTnI
test is under precise attention [21]. Implementation of this
test has changed the proportion of misdiagnosis among UA
and NSTEMI [22]. Chapman et al. asserted that the combina-
tion of hs-cTnI with clinical risk scores demonstrated some
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Table 2. Characteristics of binary logistic regression models.
Predictor Nagelkerke R2, % TPR, % TNR, % B [95% CI] p
Serotonin 74.0 80.0 95.8 0.708 [0.478-3.310] 0.001
vWF 61.9 50.0 97.2 -248.982 [-2046.878-(-180.896)] 0.001
Notes: vWF – von Willebrand factor, R2 – coefficient of determination, TPR – true positive rate,
TNR – true negative rate, B – regression coefficient, CI – confidence interval, p – probability.
Table 3. The utility of observed predictors as biomarkers of unstable angina progression
toward myocardial infarction.
Indicator Se, % Sp, % AUC Cut-off point, units LR+ [95%CI] PP (odds) [95%CI]
Serotonin 80.0 95.8 0.975 21.575 µg/ml 19.0 [6.0, 60.0] 73% (2.7) [46%, 89%]
vWF 50.0 97.2 0.973 0.114 rel.units/ml 18.0 [3.9, 80.0] 72% (2.5) [36%, 92%]
Notes: vWF -– von Willebrand factor, Se -– sensitivity, Sp -– specificity, AUC — area under the curve, LR+ – positive
likelihood ratio, PP -– posterior probability, CI -– confidence interval.
Figure 3. ROC curve with serotonin as an indicator.
benefits to rule in and rule out MI [21], while Giannitsis et al.
proclaimed the need for additional risk stratification including
other risk indicators [23]. Thus, estimated cardiovascular risk
is believed to be more important for accurate clinical manage-
ment of UA patients [22, 23]. A special feature of our study
is the analysis of serotonin and vWF concentration among
the patients with already diagnosed UA and further short-term
progression toward MI. We revealed the potential usefulness
of serotonin and vWF concentrations as prognostic markers
in UA patients.
Serotonin [24–33] and vWF [34–40] are still in eyeshot
of researchers, albeit of the long-standing history of these
substances’ investigations [41–45].
The results of studies aimed to investigate blood plasma
serotonin concentration are rather ambiguous. Kurano et al.
Figure 4. ROC curve with factor von Willebrand as an
indicator.
found no significant difference between patients with SA,
acute coronary syndrome, and even in a group with no IHD [24].
Rieder et al. revealed no association of serotonin with the sever-
ity of coronary artery disease (STEMI) [25]. At the same
time, it was shown that serotonin is involved in the serotonin-
oxidative stress axis which is engaged in the atherothrombosis
progression [26].
In our study, the increase in blood plasma serotonin in
patients with the outcome may be connected with enhanced
activation of platelets which arranges conditions for thrombo-
genesis. Ziu et al. revealed a link between elevated plasma
serotonin, abnormal intracellular serotonin signaling, and ac-
centuated platelet aggregation [41]. Besides, the active in-
volvement of serotonin in a wide range of processes may cause
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such changes. For instance, serotonin is a well-known neuro-
transmitter with its impact on a variety of psychiatric diseases
and behavioral traits [30, 31], including depression [32, 33].
According to Sanner et al. review, depression is an indepen-
dent risk factor for coronary artery disease throughout platelet
serotonin and may be associated with major adverse coronary
events (MACE) [42], which may be connected with higher
serotonin receptor density or increased platelet response to
serotonin [29].
Odaka et al. considered an increase in serotonin above
the cut-off point as a marker for coronary microvascular dys-
function [27]. Consequently, the management of UA patients
with increased risk of MI is another disputable issue. It was
shown that coronary microvascular dysfunction leads to in-
complete perfusion after angiography in about half of the pa-
tients [46].
The interaction between serotonin and its specific trans-
porter SERT is another link of the mechanism. Hence, reduced
density of SERT molecules, which clear plasma of serotonin,
may be connected with a slow decrease in plasma serotonin
concentration and leads to thrombotic events [28].
Regarding vWF concentration, we have obtained rather
controversial results. Thus, a meta-analysis of 15 studies
(960 patients with MACE and 3224 controls without adverse
events) revealed that plasma vWF level, namely its elevation,
in CAD patients might be an independent prognostic factor for
MACE. Remarkably, vWF was significantly higher in patients
with MACE unlike without the latter if examined at 24 h and
48 h after admission but not on admission. Also, the major
heterogeneity in vWF plasma levels at 24 h after admission
was detected due to the utilization of antiplatelet or anticoagu-
lation. In addition, many types of clinical disease which were
included contributed to clinical heterogeneity. Furthermore,
the timing of MACE occurrence (short-term or long-term) was
relatively unclear [34]. Previous studies demonstrated that
elevated vWF levels are an independent predictor of MACE in
CAD patients over the next 1 year [43]. Anyway, it is worthy
to highlight the differences in the design of the mentioned
studies including the current one. We suppose that in our study
patients with UA transformation into MI were characterized
by a longer period of UA duration before treatment onset. Con-
sequently, this fact may cause vWF exhaustion. Vorm et al.
registered a decrease in vWF after repeated bouts of exercise,
suggesting either adaptation of endothelial activation or ex-
haustion of endothelial vWF supplies [47]. Besides, it should
be mentioned that vWF is proteolytically degraded by the en-
zyme ADAMTS13 [35]. Yet, the latter role in cardiovascular
disorders is unclear. ADAMTS13 levels were shown to be
decreased in MI patients [44], while its increased level was
associated with elevated MI risk [45]. Also, wall share rate in-
fluence on vWF structure, conformation and concentration is
another underinvestigated point [37, 38] with some controver-
sial results [37, 39]. Furthermore, the activity of ADAMTS13
depends on vWF conformation. Globular conformation re-
mains resistant to proteolysis, whereas unfolded vWF exposes
the binding sites for ADAMTS13 on the A2 domain leading
to the cleavage of vWF multimers [37]. Taking into consid-
eration mechanochemistry of vWF it seems the tight interre-
lationship between not only vWF an ADAMTS13 but wall
share rate exist [40].
A relatively small number of patients, namely in Group 3,
is among the limitations of our study, which is partially con-
nected with the prevalence of observed phenomena. However,
we followed the exclusion criteria and 47 patients with con-
comitant disorders were excluded. Also, no angiography was
performed in our clinic, but all patients of Group 3 passed
angioplasty with stent placement.
Conclusions
We have detected the high utility of blood plasma serotonin
and vWF concentrations for the rule-in the patients with
the risk of UA transformation into MI. This fact calls for
further researches and may have practical implementation for
stratification of the patients with UA.
Prospects of Further Researches
It is reasonable to study the relations between observed sub-
stances serotonin and vWF and linked ones, namely trypto-
phan and ADAMTS13, respectively,as well as wall share rate
to elucidate possible pathogenetic mechanisms. Addition-
ally, the economic utility of biomarkers should be assessed.
Hopefully, our results will be used for further researches with
further optimization of risk factors stratification in UA pa-
tients.
Ethical Statement
This study is a fragment of the scientific-research work of
the Internal Medicine #4 Department Bogomolets National
Medical University ”Hemodynamic and coronary blood sup-
ply disturbances and ectopic myocardial activity in patients
with ischemic heart disease and diabetes mellitus, methods of
correction”, #0117U006000 in collaboration with Department
of Biochemistry, Educational and Scientific Centre ”Institute
of Biology and Medicine”, Taras Shevchenko National Uni-
versity of Kyiv, Kyiv, Ukraine (Agreement #174 of May 27,
2015).
The research was conducted according to WMA Decla-
ration of Helsinki ”Ethical principles for medical research
involving human subjects”.
The study was reviewed and approved by the local institu-
tional Research Ethics Committee of the Bogomolets National
Medical University (protocol #122 of May 29, 2019).
Informed Consent
The patients gave written consent to participate after the ex-
planation of the survey design.
Blood Plasma Serotonin and von Willebrand Factor as Biomarkers of Unstable Angina Progression Toward
Myocardial Infarction — 8/10
Conflict of Interest
The authors declare that no conflicts exist.
Financial Disclosure
The authors declared no financial support.
References
[1] World Health Organization. The top 10 causes of death
[Internet]. Available from: https://www.who.int/news-
room/fact-sheets/detail/the-top-10-causes-of-death
[2] Moran AE, Forouzanfar MH, Roth GA, Mensah GA, Ez-
zati M, Flaxman A, et al. The Global Burden of Ischemic
Heart Disease in 1990 and 2010. Circulation [Inter-
net]. 2014 Apr 8;129(14):1493–1501. Available from:
https://doi.org/10.1161/CIRCULATIONAHA.113.004046
[3] Dugani SB, Moran AE, Bonow RO, Gaziano TA.
Ischemic Heart Disease: Cost-Effective Acute
Management and Secondary Prevention. Disease
Control Priorities, Third Edition (Volume 5): Car-
diovascular, Respiratory, and Related Disorders
[Internet]. 2017 Nov 17;135–155. Available from:
https://doi.org/10.1596/978-1-4648-0518-9 ch8
[4] Alabas OA, Jernberg T, Pujades-Rodriguez M, Ruther-
ford MJ, West RM, Hall M, et al. Statistics on
mortality following acute myocardial infarction in
842 897 Europeans. Cardiovascular Research [Inter-
net]. 2019 Jul 26;116(1):149–157. Available from:
https://doi.org/10.1093/cvr/cvz197
[5] Puelacher C, Gugala M, Adamson PD, Shah A,
Chapman AR, Anand A, et al. Incidence and
outcomes of unstable angina compared with non-
ST-elevation myocardial infarction. Heart [Internet].
2019 Apr 24;105(18):1423–1431. Available from:
https://doi.org/10.1136/heartjnl-2018-314305
[6] Collet J-P, Thiele H, Barbato E, Barthélémy O, Bauer-
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